On September 16, 2026, Teva Pharmaceutical Industries Limited issued $3.2 billion in aggregate principal amount of USD Senior Notes and €1.5 billion in Euro Senior Notes through its wholly owned subsidiaries. The issuance includes €1 billion of 4.250% notes due 2033, €500 million of 4.625% notes due 2036, $1 billion each of 5.500% notes due 2034 and 5.750% notes due 2037, and $1.2 billion of 5.250% notes due 2032. Teva intends to use the net proceeds primarily to fund conditional redemptions of existing debt, including all outstanding 6.750% notes due 2028, 7.875% and 7.375% sustainability-linked notes due 2029, up to $450 million of 4.750% notes due 2027, and reduced redemptions of 4.375% notes due 2030 and 8.125% USD sustainability-linked notes due 2031. The company operates in the pharmaceutical industry.

Teva Pharmaceutical Industries Ltd. executed an amendment to its deposit agreement to terminate its American Depositary Share (ADS) program and list its ordinary shares directly on the New York Stock Exchange. The amendment establishes a mandatory exchange mechanism where each ADS converts into one ordinary share. This termination is scheduled for September 14, 2026, at the open of business in New York, after which all outstanding ADSs will be cancelled and replaced by economically equivalent NYSE-listed ordinary shares. Teva Pharmaceutical Industries Ltd. operates in the pharmaceutical industry, developing, manufacturing, and marketing generic and specialty medicines.

Teva Pharmaceutical Industries Ltd. reported second quarter 2026 revenues of $4.1 billion, a 1% decrease year-over-year in U.S. dollars, driven by lower generic sales from lenalidomide capsules offset by strong growth in innovative brands AUSTEDO and AJOVY. The company recorded a GAAP loss per share of $0.49, including $726 million in expenses related to the acquisition of Emalex Biosciences for its Tourette syndrome therapy ecopipam. Teva raised its 2026 revenue outlook to $16.5–$16.85 billion and announced a transition from American Depositary Shares to direct ordinary share listing on the NYSE, effective September 14, 2026. The company operates in the global pharmaceutical industry, specializing in generic medicines, biosimilars, and innovative biopharmaceuticals.